# US 10,307,454 B2 · Compositions and methods for the treatment of “plaques and tangles” in humans and animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,454 B2
- Document ID: US10307454B2
- Status: Granted
- Kind: B2
- Application number: 15/053,572
- Filed: 2016-02-25
- Published: 2016-09-01
- Granted: 2019-06-04
- Earliest claimed: 2015-02-27
- Assignees: Cognitive Clarity Inc.
- Applicants: Cognitive Clarity Inc.
- Inventors: Judy Cam; Thomas Lake; Qubai Hu; Joel Cummings; Alan D. Snow
- Web page: https://patentgrep.com/patent/US10307454B2

## CPC

- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 36/74: Rubiaceae (Madder family)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2236/33: involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K 2236/331: using water, e.g. cold water, infusion, tea, steam distillation or decoction
- A61K 2236/51: Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.

## Claims

### Claim 1

A method for preventing, reducing or treating amyloid plaques and/or neurofibrillary tangles in a mammalian subject comprising administering an effective amount of a composition comprising an Uncaria tomentosa extract and an oolong tea extract.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of Uncaria tomentosa extract and an oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mammalian subject has amyloidosis.

### Claim 4 (depends on 3)

The method of claim 3 wherein the amyloidosis is associated with age-associated memory loss, age-associated memory impairment (AAMI), mild cognitive impairment (MCI), Alzheimer's disease, Down's syndrome, dementia pugilistica, cognitive dysfunction syndrome, canine cognitive dysfunction, multiple system atrophy, inclusion body myositosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, Nieman-Pick disease type C, cerebral β-amyloid angiopathy, dementia associated with cortical basal degeneration, the amyloidosis of type 2 diabetes, the amyloidosis of chronic inflammation, the amyloidosis of malignancy and Familial Mediterranean Fever, the amyloidosis of multiple myeloma and B-cell dyscrasias, the amyloidosis of prion diseases, Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru, scrapie, the amyloidosis associated with carpal tunnel syndrome, senile cardiac amyloidosis, familial amyloidotic polyneuropathy, and the amyloidosis associated with endocrine tumors.

### Claim 5 (depends on 1)

The method of claim 1, wherein administration of the composition inhibits formation, deposition, accumulation, or persistence of amyloid fibrils or amyloid plaques.

### Claim 6 (depends on 1)

The method of claim 1, wherein the extracts are formulated for administration by one of the routes selected from pills, tablets, caplets, soft or hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, cold and hot beverage preparations, syrups, tea bags, aerosols, suppositories, sterile injectable solutions, or sterile packaged powders.

### Claim 7 (depends on 1)

The method of claim 1, wherein administration of the composition inhibits formation, deposition, accumulation, or persistence of beta-amyloid containing plaques.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mammalian subject has a tauopathy.

### Claim 9 (depends on 8)

The method of claim 8 wherein the tauopathy is selected from Alzheimer's disease, frontotemporal lobar degeneration with tat inclusions (FLTD-tau), Pick's disease, progressive supranuclear palsy, corticobasal degeneration, agryophlic grain disease, prion disease, amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam (also called Lytico Bodig disease), Parkinson's disease, tangle-predominant dementia, ganglioma, ganglioglioma, gangliocytoma, meningiomatosis, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease, lipofuscinosis, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), dementia pugilistic, concussion, single or repeated blows to the head, and post-traumatic stress disorder.

### Claim 10 (depends on 1)

The method of claim 1, wherein administration of the composition inhibits formation, deposition, accumulation, or persistence of tau protein containing tangles.

### Claim 11 (depends on 1)

The method of claim 1, wherein administration of the composition improves cognitive performance and/or slows cognitive decline in the mammalian subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the amount of Uncaria tomentosa extract and an oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

### Claim 13 (depends on 1)

The method of claim 1, wherein administration of the composition improves learning, memory, cognition, focus and/or concentration in the mammalian subject, wherein the mammalian subject has age-associated memory loss, age-associated memory impairment (AAMI), mild cognitive impairment (MCI) or Alzheimer's disease.

### Claim 14 (depends on 13)

The method of claim 13 wherein the amount of the combination of Uncaria tomentosa extract and oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

### Claim 15 (depends on 1)

The method of claim 1, wherein the mammalian subject has experienced single- or multiple concussions, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), post-traumatic stress disorder, brain aging, age-associated memory loss, age-associated memory impairment (AAMI), mild-cognitive impairment (MCI) or Alzheimer's disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the amount of the combination of Uncaria tomentosa extract and the oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

### Claim 17 (depends on 1)

The method of claim 1, wherein the mammalian subject is an aged dog or aged cat.